Lexeo Therapeutics, Inc.
LXEO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001907108
In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 152 institutions reported holding it in 13F filings for Q3 2026, worth $310.0M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 17, 2026, 2:23 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Mar 24, 2025 | Mar 11, 2024 |
| Operating expenses | $109.3M | $105.8M | $68.5M |
| Research and development | $63.8M | $74.1M | $53.1M |
| Selling, general and administrative | $45.5M | $31.7M | $15.4M |
| Operating income | -$109.3M | -$105.8M | -$68.5M |
| Interest expense | – | – | $205.0K |
| Income tax | $0 | – | – |
| Net income | -$100.0M | -$98.3M | -$66.4M |
| EPS, basic | $-1.86 | $-3.09 | $-12.40 |
| EPS, diluted | $-1.86 | $-3.09 | $-12.40 |
| Weighted shares, basic | 53.6M | 31.8M | 5.35M |
| Weighted shares, diluted | 53.6M | 31.8M | 5.35M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Mar 24, 2025 | Mar 11, 2024 |
| Cash and equivalents | $63.0M | $35.0M | $121.5M |
| Short-term investments | – | $86.5M | – |
| Total current assets | $188.4M | $126.1M | $124.3M |
| Property, plant and equipment | $1.14M | $1.03M | $1.06M |
| Total assets | $268.7M | $146.9M | $139.8M |
| Accounts payable | $4.86M | $6.42M | $3.79M |
| Total current liabilities | $16.8M | $22.8M | $17.2M |
| Total liabilities | $22.0M | $30.1M | $26.3M |
| Shareholders' equity | $246.7M | $116.8M | $113.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Mar 24, 2025 | Mar 11, 2024 |
| Operating cash flow | -$98.6M | -$81.2M | -$59.5M |
| Capital expenditures | $397.0K | $481.0K | $115.0K |
| Free cash flow | -$99.0M | -$81.6M | -$59.6M |
| Depreciation and amortization | $268.0K | $304.0K | $271.0K |
| Stock-based compensation | $12.1M | $12.5M | $3.04M |
| Investing cash flow | -$90.3M | -$94.1M | -$165.0K |
| Financing cash flow | $216.8M | $88.8M | $103.8M |
| Net change in cash | $28.0M | -$86.5M | $44.1M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 12, 2026 | 82.8M | +13.4% | SEC |
| Aug 10, 2026 | 82.0M | +51.9% | SEC |
| May 7, 2026 | 78.5M | +136.5% | SEC |
| Mar 27, 2026 | 74.1M | +123.2% | SEC |
| Nov 3, 2025 | 73.0M | +120.7% | SEC |
| Aug 12, 2025 | 54.0M | +63.3% | SEC |
| May 9, 2025 | 33.2M | +0.8% | SEC |
| Mar 21, 2025 | 33.2M | +24.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.